Published in Heart Disease Weekly, October 23rd, 2005
Spectranetics has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the "continuous on" lasing train to be added to its entire CliRpath product line.
Spectranetics plans to launch the expanded CliRpath Turbo product line after allowing for required software upgrades to be completed.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly